Actual pentamidine dose delivered by Respigard II nebulizer

C. S. Kim, L. Garcia, Adam Wanner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The Respigard II nebulizer system is the approved method to deliver pentamidine aerosols in the USA. Although continuous operation of the nebulizer until dryness is a designated regimen, the actual pentamidine dose delivered under the operating condition has not been thoroughly studied. Pentamidine solutions (300 mg in 6 mL water) were nebulized continuously with the Respigard II nebulizer system until dryness (40 min operation). Aerosols were delivered to the lower airways via an oropharyngeal model and sampled on a filter with a standard breathing mode of 20 breaths·min-1 frequency and 750 mL tidal volume. Intermediate samples were also obtained for the initial 20 min delivery. The pentamidine dose delivered to the mouth was 1.6% of the dose placed in the nebulizer. Of the dose delivered to the mouth, 92% was delivered during the initial 20 min period. Aerosol loss in the oropharyngeal model was 15% of the dose delivered to the mouth or 0.24% of the dose initially placed in the nebulizer. Pentamidine dose delivered to the lower airways was a very small fraction of the initial dose in the nebulizer. A partial delivery for the initial 20 min was nearly comparable to complete delivery.

Original languageEnglish
Pages (from-to)2178-2181
Number of pages4
JournalEuropean Respiratory Journal
Volume8
Issue number12
DOIs
StatePublished - Dec 29 1995
Externally publishedYes

Fingerprint

Pentamidine
Nebulizers and Vaporizers
Aerosols
Mouth
Tidal Volume
Respiration
Water

Keywords

  • aerosol delivery
  • nebulizer
  • pentamidine

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Actual pentamidine dose delivered by Respigard II nebulizer. / Kim, C. S.; Garcia, L.; Wanner, Adam.

In: European Respiratory Journal, Vol. 8, No. 12, 29.12.1995, p. 2178-2181.

Research output: Contribution to journalArticle

Kim, C. S. ; Garcia, L. ; Wanner, Adam. / Actual pentamidine dose delivered by Respigard II nebulizer. In: European Respiratory Journal. 1995 ; Vol. 8, No. 12. pp. 2178-2181.
@article{8999eeb16bb941f5bec4faa868ce2537,
title = "Actual pentamidine dose delivered by Respigard II nebulizer",
abstract = "The Respigard II nebulizer system is the approved method to deliver pentamidine aerosols in the USA. Although continuous operation of the nebulizer until dryness is a designated regimen, the actual pentamidine dose delivered under the operating condition has not been thoroughly studied. Pentamidine solutions (300 mg in 6 mL water) were nebulized continuously with the Respigard II nebulizer system until dryness (40 min operation). Aerosols were delivered to the lower airways via an oropharyngeal model and sampled on a filter with a standard breathing mode of 20 breaths·min-1 frequency and 750 mL tidal volume. Intermediate samples were also obtained for the initial 20 min delivery. The pentamidine dose delivered to the mouth was 1.6{\%} of the dose placed in the nebulizer. Of the dose delivered to the mouth, 92{\%} was delivered during the initial 20 min period. Aerosol loss in the oropharyngeal model was 15{\%} of the dose delivered to the mouth or 0.24{\%} of the dose initially placed in the nebulizer. Pentamidine dose delivered to the lower airways was a very small fraction of the initial dose in the nebulizer. A partial delivery for the initial 20 min was nearly comparable to complete delivery.",
keywords = "aerosol delivery, nebulizer, pentamidine",
author = "Kim, {C. S.} and L. Garcia and Adam Wanner",
year = "1995",
month = "12",
day = "29",
doi = "10.1183/09031936.95.08122178",
language = "English",
volume = "8",
pages = "2178--2181",
journal = "Acta tuberculosea Scandinavica",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "12",

}

TY - JOUR

T1 - Actual pentamidine dose delivered by Respigard II nebulizer

AU - Kim, C. S.

AU - Garcia, L.

AU - Wanner, Adam

PY - 1995/12/29

Y1 - 1995/12/29

N2 - The Respigard II nebulizer system is the approved method to deliver pentamidine aerosols in the USA. Although continuous operation of the nebulizer until dryness is a designated regimen, the actual pentamidine dose delivered under the operating condition has not been thoroughly studied. Pentamidine solutions (300 mg in 6 mL water) were nebulized continuously with the Respigard II nebulizer system until dryness (40 min operation). Aerosols were delivered to the lower airways via an oropharyngeal model and sampled on a filter with a standard breathing mode of 20 breaths·min-1 frequency and 750 mL tidal volume. Intermediate samples were also obtained for the initial 20 min delivery. The pentamidine dose delivered to the mouth was 1.6% of the dose placed in the nebulizer. Of the dose delivered to the mouth, 92% was delivered during the initial 20 min period. Aerosol loss in the oropharyngeal model was 15% of the dose delivered to the mouth or 0.24% of the dose initially placed in the nebulizer. Pentamidine dose delivered to the lower airways was a very small fraction of the initial dose in the nebulizer. A partial delivery for the initial 20 min was nearly comparable to complete delivery.

AB - The Respigard II nebulizer system is the approved method to deliver pentamidine aerosols in the USA. Although continuous operation of the nebulizer until dryness is a designated regimen, the actual pentamidine dose delivered under the operating condition has not been thoroughly studied. Pentamidine solutions (300 mg in 6 mL water) were nebulized continuously with the Respigard II nebulizer system until dryness (40 min operation). Aerosols were delivered to the lower airways via an oropharyngeal model and sampled on a filter with a standard breathing mode of 20 breaths·min-1 frequency and 750 mL tidal volume. Intermediate samples were also obtained for the initial 20 min delivery. The pentamidine dose delivered to the mouth was 1.6% of the dose placed in the nebulizer. Of the dose delivered to the mouth, 92% was delivered during the initial 20 min period. Aerosol loss in the oropharyngeal model was 15% of the dose delivered to the mouth or 0.24% of the dose initially placed in the nebulizer. Pentamidine dose delivered to the lower airways was a very small fraction of the initial dose in the nebulizer. A partial delivery for the initial 20 min was nearly comparable to complete delivery.

KW - aerosol delivery

KW - nebulizer

KW - pentamidine

UR - http://www.scopus.com/inward/record.url?scp=0028829390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028829390&partnerID=8YFLogxK

U2 - 10.1183/09031936.95.08122178

DO - 10.1183/09031936.95.08122178

M3 - Article

VL - 8

SP - 2178

EP - 2181

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

SN - 0903-1936

IS - 12

ER -